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Ubiquitination
AcetylationPhthalates, phthalic acid esters, are widely used as plasticizers to produce polymeric materials in industrial pro-
duction of plastics and daily consumable products. Animal studies have shown that di(2-ethylhexyl)phthalate
(DEHP) may cause toxic effects in the rat brain. In the present study, chronic exposure to DEHP (0.1–100 μM)
caused dose-dependent cell death via the activation of caspase-3 in neuroblastoma cells. Intriguingly, this harm-
ful effect was prevented by the pan-histone deacetylase (HDAC) inhibitor trichostatin A, by the class II HDAC
inhibitor MC-1568, but not by the class I HDAC inhibitor MS-275. Furthermore, DEHP reduced speciﬁcity protein
3 (Sp3) gene expression, but not Sp3 mRNA, after 24 and 48 h exposures. However, Sp3 protein reduction was
prevented by pre-treatment with MC-1568, suggesting the involvement of class II HDACs in causing this effect.
Then, we investigated the possible relationship between DEHP-induced neuronal death and the post-
translational mechanisms responsible for the down-regulation of Sp3. Interestingly, DEHP-induced Sp3 reduc-
tion was associated to its deacetylation and polyubiquitination. Co-immunoprecipitation studies showed that
Sp3 physically interacted with HDAC4 after DEHP exposure, while HDAC4 inhibition by antisense
oligodeoxynucleotide reverted the DEHP-induced degradation of Sp3. Notably, Sp3 overexpression was able to
counteract the detrimental effect induced by DEHP. Taken together, these results suggest that DEHP exerts its
toxic effect by inducing deacetylation of Sp3 via HDAC4, and afterwards, Sp3-polyubiquitination.
© 2014 Elsevier Inc. All rights reserved.Introduction
The di(2-ethylhexyl)phthalate (DEHP) is the most common com-
mercial plasticizer used in the production of polyvinylchloride plastics,
which have a variety of applications including storage of human
blood, food packaging, cosmetics, and medical devices (Kavlock et al.,
2002). It has been reported that at an appropriate concentration DEHP
exerts toxic effects on the central nervous system following both prena-
tal and postnatal exposures. Indeed, prenatal exposure to DEHPdisrupts
brain development and decreases brain weight in rats (Tanida et al.,
2009). Particularly, it has been shown that DEHP poses a negative im-
pact on hippocampal development in male rats (Smith et al., 2011;C, histone deacetylase; Sp1, Sp3
deoxynucleotide; MS, missense
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iero), cformisa@unisannio.itTanida et al., 2009). Postnatal DEHP exposure is known to cause motor
hyperactivity (Masuo et al., 2004b) and signiﬁcantly decreases the
number of midbrain dopaminergic neurons (Masuo et al., 2004a;
Tanida et al., 2009). In humans, association between phthalate exposure
and autism spectrum disorders has been suggested (Testa et al., 2012),
although this conclusion is limited by relatively small sample sizes
(Rossignol et al., 2014).
Several lines of evidence indicate that alteration in the expression
and function of histone deacetylases (HDACs) (Abel and Zukin, 2008)
and speciﬁcity protein (Sp) transcription factors is involved in neurode-
generation (Qiu et al., 2006; Ravache et al., 2010; Ryu et al., 2003;
Santpere et al., 2006). Four different classes of HDACs are known:
class I HDACs (1–3 and 8) are constitutively nuclear proteins; class II
HDACs (4–7, 9, and 10) are expressed in a cell-speciﬁc manner and
shuttle between the nucleus and cytoplasm (de Ruijter et al., 2003);
class III HDACs or sirtuins consist of seven members (SIRT1–SIRT7);
and class IV HDACs, currently composed of one member, HDAC11, of
which little is known (Haberland et al., 2009). Sp transcription factors
are a family of proteins containing zinc-ﬁnger motifs that bind to G-C/
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expression of a large number of genes, including most “housekeeping”
genes (Mao et al., 2007). Interestingly, it has been shown that forced ex-
pression of Sp1 or Sp3 is neuroprotective (Ryu et al., 2003). Since it has
been demonstrated that HDACs and Sp transcription factors are in-
volved in several neurotoxic insults such as those induced by
polychlorinated biphenyls (Formisano et al., 2011), brain ischemia
(Formisano et al., 2013), and Huntington's disease (Ravache et al.,
2010), we investigated the possible relationship between DEHP-
neurotoxicity and Sp transcription factors in neuroblastoma SH-SY5Y
cells.
Materials & methods
Drug and chemicals. Di(2-ethylhexyl) phthalate (DEHP) (stock solu-
tion 2.56M) (N-11226; lot: 284400) was purchased from Chem Service
(West Chester, USA). Culture media and sera were obtained from
Invitrogen (Milan, Italy). The HDAC inhibitors trichostatin A (TSA)
(T8552) (stock solution 1 μM), MS-275 (EPS002) (stock solution
100 μM), MC-1568 (M1824) (stock solution 1 M), and MG-132
(C2211) (stock solution 40 mM) were obtained from Sigma-Aldrich
(St. Louis, MO) and pan-caspase inhibitor, z-VAD-fmk (Merck
Chemicals, Nottingham, UK) (stock solution 100 mM). All chemicals
were diluted in a cell culture medium. For those requiring dilution in
DMSO, the ﬁnal DMSO concentration was 0.1%. DMSO was added to
the control cells at themaximum concentration used for the treatments.
Under these conditions, DMSO did not induce cellular toxicity.
Cell lines and culture conditions. Human neuroblastoma SH-SY5Y cells
(IRCCS Azienda Ospedaliera Universitaria San Martino-IST-Istituto
Nazionale per la Ricerca sul Cancro, Genoa, Italy) were grown as mono-
layers in Dulbecco's modiﬁed Eagle's medium (DMEM) with 10% (v/v)
fetal bovine serum (FBS), L-glutamine (2 mM), pyruvic acid (1 mM), 1×
non-essential amino acids and 1× antibiotics. All experiments were con-
ducted in cultures containing cells between the 15th and 25th passages.
After 24 h of cell seeding, DEHP (0.1 μM, 10 μM, 50 μM, 100 μM) was
added in DMEMmedium containing 1% FBS, for 24 and 48 h. Oligoden-
drocyte MO3.13 progenitor cells were prepared as described previously
(Boscia et al., 2012). Animal studies have been approved by the Animal
Care Committee of “Federico II”, University of Naples, Italy. Cortical neu-
rons were prepared from 17-day-old Wistar rat embryos (Charles River,
Calco, Milan, Italy) as previously described (Formisano et al., 2013) and
used after 10 days. Neurons were grown in modiﬁed Eagle medium/F1
containing 30% glucose, 5% of deactivated fetal bovine serum and 5%
horse serum, L-glutamine (2 mmol/l), penicillin (50 U/ml), and strepto-
mycin (50 μg/ml). For all the experiments with HDAC inhibitors and
pan-caspase inhibitor, after cell seeding, cells were pre-treated for 2 h
with TSA (50 nM), MS-275 (5 μM) and MC-1568 (5 μM) and for 3 h z-
VAD-fmk.
Cell transfection. Anti-sense and missense oligonucleotides (ODNs)
speciﬁcally designed for HDAC4 (HDAC4 AS and HDAC4 MS) were
transfected into SH-SY5Y cells (70% conﬂuence) and cortical neurons
(60% conﬂuence) with Lipofectamine in Optimem medium, according
to the protocol by themanufacturer (Invitrogen Srl, S. GiulianoMilanese
Italy). Afterwards, Optimem was removed and a fresh medium was
added for 24 and/or 48 h, alone or in combination with DEHP 50 μM.
In brief, oligonucleotides (1 μM) were dissolved in Lipofectamine and
then incubated at room temperature for 30 min before being added to
the culture medium. Nucleotide sequences were designed to target
the human HDAC4 mRNA (NM_006037.3): HDAC4 AS and HDAC4 MS
are GCCCACGCCCCACCAGCAGGC (7317–7337) and GCCCACGCCCCATT
GGCAGGC. ODN target rat HDAC4 mRNA were already published
(XM_343629.3) (Matsuda et al., 2011). pN3 and pN3–Sp3, the plasmid
carrying Sp3 cDNA, were kindly provided by Prof. G. Suske (Marburg,
Germany). Transient transfection of 1 μg DNA in 12-multiwell plateswas performed using Lipofectamine in Optimem, for 6 h in SH-SY5Y
cells and for 2 h in cortical neurons (1 × 105 cells/well). Finally, cells
were exposed to 50 μM DEHP for 48 h and subjected to Annexin V. For
Western blot analysis, cells were plated in 100 mm dishes, and tran-
siently transfected with 15 μg of DNA using Lipofectamine in Optimem,
for 6 h in SH-SY5Y cells and for 2 h in cortical neurons. After all, cells
were exposed to 50 μM DEHP for 48 h. To evaluate cell transfection
efﬁciency, constructs and ODNs were mixed with a plasmid encoding
the enhanced green ﬂuorescent protein marker. Transfection efﬁciency
was ≅80% for SH-SY5Y cells and ≅70% for cortical neurons (data not
shown).
Determination of cell viability. Cell viability was determined using the
dimethylthiazolyl-2-5-diphenyltetrazolium-bromide (MTT, Sigma)
staining, at 24 and 48 h after DEHP treatments in SH-SY5Y cells and ol-
igodendrocyte MO3.13 progenitor cells at concentrations of 0.1 μM,
10 μM, 50 μM and 100 μM and in cortical neurons at concentrations of
0.01 μM, 0.1 μM, 10 μM, 50 μM, and 100 μM.
For the MTT with HDAC inhibitors and z-VAD-fmk, SH-SY5Y cells
were ﬁrst seeded into 12 well-plates, treated with 0.1% DMSO (CTL),
and pre-treated for 2 h with TSA, MS-275, and MC-1568 and for 3 h
with z-VAD-fmk. Cells were exposed to DEHP (50 μM) for 48 h. After
treatment, cells were incubatedwith 0.5 mg/mlMTT for 1 h at 37 °C. Af-
terwards, the supernatant was discarded, the insoluble formazan pre-
cipitates were dissolved in 0.5 ml DMSO, and the absorbance was
detected at 540 nm. Each experiment was performed in triplicate.
Values from each treatment were reported as a percentage of the rela-
tive control.
Annexin V staining. SH-SY5Y cells (1 × 105 cells/well) were seeded
into each well of a 12-well plate and pre-treated with for 2 h with
HDAC inhibitors or for 6 h with z-VAD-fmk. In the experiments of Sp3
overexpression and HDAC4 knock-down, SH-SY5Y (1 × 105 cells/well)
and cortical neurons (1 × 105 cells/well) were transfected with pN3–
Sp3 plasmid carrying Sp3 cDNA and with the empty vector pN3 or
with HDAC4 AS and HDAC4 MS. For apoptosis staining experiments,
cells were exposed to DEHP (50 μM) for 48h. 5 × 105 cells were harvest-
ed and stained according to the Tali Apoptosis Kit instructions
(Invitrogen, Molecular Probes, Life Technologies). Brieﬂy, cells were in-
cubated with Annexin V Alexa Fluor 488 for 20 min at room tempera-
ture and then deposed in suspension in a slide. Fluorescence was
scanned with the Tali Image based Cytometer (Invitrogen, Life Technol-
ogies). Apoptotic cells were Annexin V positive and the negative sample
was acquired for control staining. The cells were analyzed using a Tali™
Image byuring captures 10 images of a stained sample, automatically
analyzes the images using digital image-based cell counting and
ﬂuorescence-detection algorithms, and displays an accurate quantita-
tive analysis of live, dead, and apoptotic cell populations. All measure-
ments were performed in triplicate.
Western blot analysis. Cells were lysed in buffer containing 50 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, protease
and phosphatase inhibitors. Theywere incubated for 1 h on ice and cen-
trifuged at 12,000 rpm for 15min at 4 °C. Supernatants (100 μg for Sp1,
3, 4, pro-caspase, cleaved caspase 3 and 50 μg for Acetyl-H3 and Acetyl-
tubulin) were incubated with the following buffer: 62.5 mM Tris–HCl,
pH 6.8, 2% SDS, 10% glycerol, and 5% 2-mercaptoethanol. The extracts
were electrophoreted through SDS-8% polyacrylamide gel for the detec-
tion of Sp1, 3, 4, pro-caspase and cleaved caspase 3, and through SDS-
12% polyacrylamide gel for Acetyl-H3 and Acetyl-tubulin. The gels
were electroblotted onto polyvinylidene diﬂuoride membrane
(Amersham Biosciences) in transfer buffer (48 mM Tris–HCl, 39 mM
glycine, and 20% methanol). Membranes were then treated with a
blocking solution for 2 h at room temperature (RT) (10% dry milk and
0.1% Tween 20 in Tris-buffered saline) and incubated overnight at 4 °C
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7272, monoclonal antibody, Santa Cruz Biotechnology Inc.), anti-
cleaved caspase-3 (1:1000, cat: AAP-113, polyclonal antibody, Stressgen
Biotechnologies Corporation), anti-Sp1 (1:1000, cat: sc-14027, poly-
clonal antibody, Santa Cruz Biotechnology Inc.), anti-Sp4 (1:1000, cat:
sc-645, polyclonal antibody, Santa Cruz Biotechnology Inc.), anti-Sp3
(1:500, sc-644, polyclonal antibody, Santa Cruz Biotechnology Inc.),
anti Acetyl-H3 (1:1000, cat: 06-599, rabbit polyclonal antibody,
Millipore corporation), anti-acetyl-tubulin (1:10,000, T7451, mouse
monoclonal antibody, Sigma-Aldrich), anti-tubulin (1:1000, cat: sc-
654, polyclonal antibody, Santa Cruz Biotechnology Inc.), anti-HDAC4
(1:1000, cat: sc-11418, polyclonal antibody, Santa Cruz Biotechnology
Inc.) and anti-β-actin (1:2000, A3853, monoclonal antibody, Sigma-
Aldrich, St. Louis, MO). For Sp3, three different Sp3 isoforms of almost
115, 70 and 68 kDa have been detected; we decided to analyze only
the 115-kDa isoform, since it is biologically active (Ammanamanchi
and Brattain, 2001). Immunoreactive bands were detected using an en-
hanced chemiluminescence reagent (GE Healthcare), and analyzed by
the Chemi-Doc Imaging System (Bio-Rad Laboratories, Hercules, CA).
The experiments were replicated three times.Chromatin immunoprecipitation (ChIP) assay and quantitative real-time-
PCR. Cells plated in 100-mm dishes (5 × 106 cells per dish),
and treated with DEHP (50 μM) alone or after pretreatment 2 h
with MC-1568 were cross-linked with 1% formaldehyde for
10 min at room temperature, crosslinking was stopped by incu-
bating cells with glycine (0.125 M) for 5 min at room temperature.
Cells were washed twice with cold PBS containing protease inhib-
itors, harvested, and centrifuged at 4000 rpm at 4 °C for 3 min. The
cellular pellet was lysed in buffer containing 50 mM Tris-HCl,
pH 8.1, 1% SDS, 10 mM EDTA, and protease inhibitors. After that,
to keep cell samples at a low temperature, it was fragmented by
sonication into 200–500 bp fragments with the Bioruptor instru-
ment (Diagenode) for 20 min at high potency in a tank ﬁlled
with ice/water. Samples were centrifuged at 14,000 rpm for
15 min at 4 °C and, then, diluted in IP buffer (16.7 mM Tris–HCl,
pH 8.1, 167 mM NaCl, 1.1% Triton X-100, 1.2 mM EDTA, 0.01%
SDS, protease inhibitors). A fraction of the sample was conserved
as an input. The sample was shaken gently at 4 °C for 2 h with pro-
tein A (Protein A Agarose/Salmon Sperm DNA, 16-157C, Upstate).
After centrifugation at 2000 rpm at 4 °C for 1 min, the supernatant
was immunoprecipitated overnight at 4 °C with a 10 μl anti-Sp3
antibody (sc-644, Santa Cruz Biotechnology Inc.). IgG rabbit
antibody was used as a negative control. After incubation with
protein A (Protein A Agarose/Salmon Sperm DNA, 16-157C, Up-
state) at 4 °C for 4 h, beads were sequentially washed with high-
salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–
HCl, pH 8.1, 500 mM NaCl), low-salt buffer (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris–HCl, pH 8.1, 150 mM NaCl), LiCl
buffer (0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM
EDTA, and 10 mM Tris–HCl, pH 8.1) and twice with Tris/EDTA
buffer (10 mM Tris-HCl, pH 8.1 and 1 mM EDTA). The precipitates
were extracted twice using immunoprecipitation elution buffer
(1% SDS, 0.1 M NaHCO3) and NaCl (5 M) was added to the total el-
uates and incubated at 65 °C for 6 h. DNA fragments were puriﬁed
by phenol–chloroform extraction and ethanol precipitation, and
dissolved in sterile water. DNA samples were then analyzed for
real-time PCR using Fast SYBR Green Master Mix (Applied
Biosystems). Data obtained from three different experiments of
real time PCR were expressed as a percentage of the relevant con-
trols, all normalized for the DNA input. IgG controls were per-
formed (not shown), and the values were subtracted from
results for ChIP samples. The oligonucleotides used for the ampli-
ﬁcation of immunoprecipitated DNA of cyclooxygenase-2 (COX-
2) and Neuroglobin (Ngb) promoter regions were already beenpublished (Xu and Shu, 2007; Zhang et al., 2011). The experi-
ments were replicated three times.
Reverse transcription-real time PCR. Total RNAwas isolated according
to the supplier's protocol (TRI Reagent; Sigma-Aldrich, St. Louis, MO)
and treated with DNAse I (1 U/μl) for 30 min at RT. The ﬁrst strand
cDNA synthesis was achieved with SuperScript reverse transcriptase
(Invitrogen S. Giuliano Milanese, Italy). Real-time quantitative PCR
was performed with the ﬂuorescent dye SYBR Green methodology,
using the FAST SYBR Green Master Mix (Applied Biosystem) and per-
formed in the ABI Prism 7700 (Applied Biosystem). Primer pairs for tar-
get genes were the following: for Sp1 Forward (Fw) 5′-TTGAAAAAGG
AGTTGGTGGC-3′, and Reverse (Rv) 5′-TGCTGGTTCTGTAAGTTGGG-3′
(NM_001251825.1), Sp3 Fw 5′-CCAGGATGTGGTAAAGTCTA-3′, Rv 5′-
CTCCATTGTCTCATTTCCAG-3′ (NM_001172712.1), Sp4 Fw 5′-GCGGAA
AAAGAGGCAGAGCC-3′, Rv 5′-CTTCTGTAGCCATCGCCGC-3′ (NM_
003112.3), HDAC4 Fw 5′-CAGATGGACTTTCTGGCC-3′, Rv 5′-CTTGAGCT
GCTGCAGCTTC-3′ (NM_006037.3), HDAC5 Fw 5′-TGGCCTCGGATGGG
CATTAG-3′, Rv 5′-CATCCCATCTGCCGACTCGT-3′ (NM_001015053.1),
HDAC6 Fw 5′-ACCTAGGTTAGCTGAGCGGA-3′, Rv 5′-TGCTCGAGGCTA
GAGGAGTT-3′ (NM_006044.2), HDAC7 Fw 5′-CTCGGAGGCTGACAGTGA
CC-3′, Rv 5′-GGTCCAGGAGGAGAATGGGC-3′ (NM_001098416.2),
HDAC9 Fw 5′-AGCAACCAGGCAGTCACCTT-3′, Rv 5′-GCCTGCTCCCCAGA
TTCCAT-3′ (NM_001204148.1), HDAC10 Fw 5′-TTGACTCAGCCATCGG
GGAC-3′, Rv 5′-TAGGGCACTCTGACATGGCG-3′ (NM_032019.5), ribo-
somal protein L19 (L19) Fw 5′-CTAGTGTCCTCCGCTGTGG-3′, Rv 5′-
AAGGTGTTTTTCCGGCATC-3′ (NM_032019.5), Ngb Zhang et al., 2011,
COX-2 (Alique et al., 2007) and HDAC class I (Kawabata et al., 2010).
Samples were ampliﬁed simultaneously in triplicate in one assay run,
and the threshold cycle (Ct) value for each experimental group was de-
termined. Normalization of data was performed using L19. To evaluate
differences inmRNA content among groups, normalized valueswere en-
tered into the formula 2−ΔΔCt. All data were normalized to control
“housekeeping genes”, known to be stable after DEHP treatment, actin,
and HPRT (hypoxanthine phosphoribosyl transferase). Although none
of these genes showed a statistically signiﬁcant change following DEHP
exposure, the gene which exhibited the least variability was L19 (not il-
lustrated). The experiments were replicated four times.
Immunoprecipitation. Cells were seeded into a 100-mm tissue culture
and grown to approximately 80% conﬂuence. Cells were treated with
DEHP (50 μM), alone or pre-treated for 2 h with MC-1568 (5 μM), and
transiently transfected with HDAC4 AS (10 μM). Total cell extracts for
each group were resuspended using immunoprecipitation lysis buffer
(50 mM Tris–HCL, pH 7.5, 1, Triton 1%, β-glicerol 10 mM, NaF 100
mM,Na3VO4 100mM, 150mMNaCl, and 1mMEDTA)with the addition
of protease inhibitor cocktail (1/100) P-8140 (Sigma). Aliquots of 1500
μg were used for the experiments in a ﬁnal volume of 1 ml, followed by
the addition of 20 μl of protein A/G PLUS-agarose beads (Santa Cruz Bio-
technology). The reactionswere placed on a rotator at 4 °C for 4 h. A 900
μl aliquot of supernatant was used for the immunoprecipitation. Rabbit
polyclonal anti-Sp3 (3 μg) (sc-644) HDAC3 (3 μg) (sc-11417) or normal
rabbit IgG (3 μg) was added to either treatment set, followed by the ad-
dition of 20 μl of protein A/G PLUS-agarose beads. The samples were
then placed on a rocker at 4 °C over-night. The supernatants were re-
moved, and washed two times with 500 μl of cold PBS 1× plus protease
inhibitors. The pellets were resuspended in 20 μl of loading buffer,
boiled for 10 min and centrifuged. The immunoprecipitated superna-
tant was separated by SDS-10% and blotted onto polyvinylidene
diﬂuoride membrane (Amersham Biosciences) in transfer buffer (48
mM Tris–HCl, 39 mM glycine, and 20% methanol). Membranes were
then treated with a blocking solution for 2 h at RT (10% dry milk and
0.1% Tween 20 in Tris-buffered saline) and incubated overnight at 4°
with anti-ubiquitin (1:1000, cat: sc-8017, mouse monoclonal antibody,
Santa Cruz Biotechnology Inc.), anti-acetyl-lysine (1:1000, cat: 9441,
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bit polyclonal antibody, Santa Cruz Biotechnology Inc.), and anti-
HDAC4 (1:1000, cat: sc-11418, polyclonal antibody, Santa Cruz Biotech-
nology Inc.). Immunoreactive bands were detected using an enhanced
chemiluminescence reagent (GE Healthcare), and analyzed by the
Chemi-Doc Imaging System (Bio-Rad Laboratories, Hercules, CA).
Statistical analysis. Data are expressed as mean ± S.E.M. Statistical
comparisons among the experimental groups were performed using
one way ANOVA followed by the Newman–Keuls test. P value b 0.05
was considered statistically signiﬁcant.
Results
DEHP-induced apoptotic cell death is inhibited by class II HDAC inhibitor
MC-1568 in SH-SY5Y cells
When SH-SY5Y cells were exposed to different concentrations of
DEHP (0.1–100 μM) for 24 and 48 h, a dose-related reduction of cell
viability was found byMTT assay (Figs. 1A,B). 50 μMDEHP exposure re-
sulted in damage to approximately 50% of cells, and was thereforeFig. 1. Effect of DEHP on SH-SY5Y cell survival. A,B) Effect of 24 and 48 h DEHP (0.1, 10, 50 and 1
four independent experimental sessions. *P b 0.05 vs. control (CTL), CTL+ vehicle, and 0.1 μMD
alone or with 50 nM trichostatin A (TSA), 5 μMMS-275, and 5 μMMC-1568 on the mitochon
sessions. Cells were pre-treated with TSA, MS-275, and MC-1568 for 2 h before DEHP addi
caspase-3, and tubulin levels in control conditions and 48 h after 10, 50, and 100 μM DEHP ex
representmean± S.E.M. obtained from three independent experimental sessions. *P b 0.05 vs. C
blots of pro-caspase-3, cleaved caspase-3, and tubulin levels in CTL conditions orwith 48 h 50 μM
3 to tubulin. Bars representmean± S.E.M. obtained from four independent experimental sessio
h alone or with 50 nM trichostatin A (TSA), 5 μMMS-275, 5 μMMC-1568 and z-VAD-fmk 5
represent mean ± S.E.M. obtained in three independent experimental sessions. Cells were
DEHP addition. *P b 0.05 vs. CTL; **P b 0.05 vs. DEHP.chosen for all experiments, unless indicated otherwise. Notably, DEHP
(0.1–100 μM) did not induce toxicity in oligodendrocyte MO3.13 pro-
genitor cells at 24 and 48 h (Supplementary Figs. 1A,B).
Treatment with pan-HDAC inhibitor trichostatin A (TSA; 50 nM)
(Formisano et al., 2013) and class II HDAC inhibitor MC-1568 (5 μM)
(Nebbioso et al., 2010; Spallotta et al., 2013), but not class I HDAC inhib-
itor MS-275 (5 μM) (Marinova et al., 2011), resulted in a signiﬁcant im-
provement in cell viability, compared to cultures exposed to DEHP
alone. TreatmentwithHDAC inhibitors alone had noeffect on cell viabil-
ity (Fig. 1C).
TheHDAC speciﬁcity of TSA,MS-275, andMC-1568was validated by
measuring their effects on the levels of acetylated forms of histone H3
(indicating activity of class I and II HDACs) and tubulin (indicating activ-
ity of class II HDACs) (Galmozzi et al., 2013). Results showed that TSA
and MC1568 increased the acetylation of histone H3 and tubulin,
whereas MS-275 increased the acetylation of histone H3, but not of tu-
bulin, compared to the controls (Supplementary Fig. 2A). Furthermore,
SH-SY5Y cells exposed to DEHP showed a dose-related increase of ac-
tive caspase-3, that was absent in control cells (Fig. 1D). This increase
was completely inhibited by pre-treatment withMC1568 (Fig. 1E). Fur-
thermore, apoptosis was quantiﬁed using FITC-conjugated Annexin V00 μM) exposure on themitochondrial activity. Bars represent mean± S.E.M. obtained in
EHP; **P b 0.05 vs. 10 μMDEHP; ***P b 0.05 vs. 50 μMDEHP. C) Effect of 50 μMDEHP at 48h
drial activity. Bars represent mean ± S.E.M. obtained in ﬁve independent experimental
tion. *P b 0.05 vs. CTL; **P b 0.05 vs. DEHP. D) Western blots of pro-caspase-3, cleaved
posure. Graphs show the quantiﬁcation of the ratio of cleaved caspase-3 to tubulin. Bars
TL; **P b 0.05 vs. 10 μMDEHP; ***P b 0.05 vs. 50 μMDEHP;N.D., not detectable. E)Western
DEHP alone orwithMC-1568. Graphs showquantiﬁcation of the ratio of cleaved caspase-
ns. *P b 0.05 vs. CTL; **P b 0.05 vs. DEHP; N.D., not detectable. F) Effect of 50 μMDEHP at 48
0 μM on apoptosis determined using the Annexin V-Alex Fluor 488 Apoptosis kit. Bars
pre-treated with TSA, MS-275, and MC-1568 for 2 h and 3 h with z-VAD-fmk before
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cells were positive for Annexin V following 48 h of treatment with
DEHP (50 μM), compared with only 8% of cells in the control group. In-
terestingly, TSA, MC-1568 and z-VAD-fmk, but not MS-275 completely
reverted DEHP-induced apoptosis (Fig. 1F).Effect of DEHP exposure on Sp1, Sp3 and Sp4 expression in SH-SY5Y cells
To verify the involvement of pro-survival transcription factors Sp1,
Sp3, and Sp4 in DEHP-induced cell death, we evaluated Sp1, Sp3 and
Sp4 protein levels byWestern blot. It was found that DEHP (50 μM) sig-
niﬁcantly decreased the levels of Sp3, but not Sp1 and Sp4, at 24 and 48
h compared to controls (Figs. 2A–C). qRT-PCR analysis revealed that
Sp1, Sp3 and Sp4 mRNAs were not signiﬁcantly modiﬁed, compared
to the control, 24 and 48 h after DEHP treatment (Figs. 2D–F).Effect of proteasomal inhibitor MG-132 and class II HDAC inhibitor MC-
1568 on DEHP-induced reduction of Sp3 in SH-SY5Y cells
Immunoprecipitation with a polyclonal anti-Sp3 antibody, followed
by immunoblottingwith amonoclonal antibody against acetyl lysine or
ubiquitin, revealed that Sp3 was deacetylated and ubiquitinated after
24 h treatment with 50 μM DEHP (Figs. 3A,B). DEHP-induced
deacetylation and ubiquitination of Sp3 was prevented when cells
were pre-treated with MC-1568 (5 μM; Figs. 3A,B). These results indi-
cate that DEHP induced Sp3 deacetylation and subsequently its degra-
dation via ubiquitination. Indeed, 2 h pre-treatment of SH-SY5Y cells
with MC-1568 (5 μM) or MG-132 (1 μM)was able to both signiﬁcantly
increase Sp3 (Figs. 3C,E) and prevent its protein reduction induced by
48 h treatment with DEHP (Figs. 3D,F). To further verify the functional
consequence of Sp3 inhibition induced by DEHP, alone or after 2 h
pre-treatment with MC-1568 (5 μM), ChIP with Sp3 antibody and
qRT-PCR analysis for two known Sp3 target genes, COX-2 (Xu andFig. 2.DEHP-induced Sp3 protein reduction in SH-SY5Y cells. A–C)Western blots of Sp1, Sp3, an
quantiﬁcation of the ratio of Sp1, Sp3, and Sp4 to tubulin. Bars represent mean ± S.E.M. obtain
Effect of 24 and 48 h DEHP (50 μM) exposure on Sp1, Sp3, and Sp4 mRNA expression detected
sessions.Shu, 2007) and Ngb (Zhang et al., 2011), both constitutively expressed
in SH-SY5Y cells (Alique et al., 2007; Fordel et al., 2006),was conducted.
MC-1568 and MG-132 increased Sp3 binding on COX-2 and Ngb
promoter sequence (Figs. 3G,I), in parallel with an increase of COX-2
and Ngb mRNAs compared to the control group (Figs. 3M,O). As
shown in Figs. 3H,L, at 24 h DEHP induced a decrease of Sp3 binding
on COX-2 and Ngb genes compared to the control group and this effect
was reverted by the pre-treatment with MC1568. Particularly, MC1568
reverted DEHP-induced COX-2 and Ngb mRNA decrease (Figs. 3N,P).
Effect of HDAC4 knock-down and Sp3 overexpression on cell survival in
DEHP-treated SH-SY5Y cells and cortical neurons
When cortical neurons were exposed to different concentrations of
DEHP (0.1–100 μM) for 24 and 48 h, a dose-related reduction of cell
viability was found by MTT assay (Supplementary Figs. 3A,B). As was
found in SH-SY5Y cells, 50 μMDEHP exposure resulted in damage to ap-
proximately 50% of cells, and was therefore chosen for all experiments
in cortical neurons.
To evaluate the role of Sp3 in DEHP-induced toxicity, Sp3 was
overexpressed in cortical neurons and in SH-SY5Y cells. As shown in
Figs. 4A,D, the overexpression of Sp3 through cDNA transfection
reverted DEHP-induced Sp3 reduction. Notably, Sp3 overexpression
did not modify DEHP-induced HDAC4 increase, in both SH-SY5Y cells
and cortical neurons (Figs. 4B,E). Interestingly, Sp3 cDNA and ODN anti-
sense (AS) HDAC4 transfection were able to signiﬁcantly reduce the
number of Annexin V positive cells following 48 h DEHP exposure in
SH-SY5Y cells and cortical neurons, whereas the empty vector and mis-
sense ODN (MS) controls did not (Figs. 4C,F).
DEHP exposure determines the association of HDAC4 with Sp3 in SH-SY5Y
cells
To further investigate themolecular link between class II HDACs and
Sp3 in DEHP-treated SH-SY5Y cells, qRT-PCR was performed withd Sp4 protein levels in control conditions and 50 μMDEHP at 24 and 48 h. Graphs show the
ed from four independent experimental sessions. *P b 0.05 vs. CTL; **P b 0.05 vs. all. D–F)
by RT-PCR. Bars represent mean ± S.E.M. obtained from four independent experimental
Fig. 3. DEHP-induced Sp3 protein reduction is associated with its deacetylation and poly-ubiquitination in SH-SY5Y cells. A) RepresentativeWestern blot showing immunoprecipitation
between Sp3 and acetyl-lysine after 24 h 50 μMDEHP treatment alone or after 2 h pre-treatment with MC-1568. B) RepresentativeWestern blot showing immunoprecipitation between
Sp3 and poly-ubiquitin after 24 h 50 μM DEHP treatment alone or after 2 h pre-treatment with MC-1568. C–F) Representative Western blots of Sp3 protein levels in control conditions
(CTL), after 2 h pre-treatment with MC-1568 and MG-132 (C,E), after DEHP exposure alone or with 2 h pre-treatment with MC-1568 and MG-132, respectively (D,F). Graphs show the
quantiﬁcation of the ratio of Sp3 to tubulin. Bars represent mean ± S.E.M. obtained from four independent experimental sessions. *P b 0.05 vs. CTL. G–L) Quantiﬁcation by ChIP assay
of Sp3 binding on COX-2 and Ngb promoter in control conditions (CTL), after 2 h pre-treatment with MC-1568 (G,I), after DEHP exposure alone or with 2 h pre-treatment with MC-
1568 and MG-132, respectively (H,L). M–P) Quantiﬁcation by real time RT-PCR on COX-2 and Ngb mRNA expression in control conditions (CTL), after 2 h pre-treatment with MC-
1568 (M,O), after DEHP exposure alone or with 2 h pre-treatment with MC-1568 andMG-132, respectively (N,P). Bars represent mean± S.E.M. obtained from three independent exper-
imental sessions for ChIP and RT-PCR experiments. *P b 0.05 vs. CTL.
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(Hornan et al., 2007; Oehme et al., 2013; Subramanian et al., 2011; Sun
et al., 2013). DEHP induced a signiﬁcant increase in HDAC4 at 24 and 48
h and a signiﬁcant reduction of HDAC5 at 48 h, while HDAC class I and
HDACs 6, 7 and 10were not signiﬁcantlymodiﬁed (Figs. 5A,B). Interest-
ingly, the HDAC4 mRNA increase was in parallel with the HDAC4 pro-
tein (Figs. 5B,C). Immunoprecipitation results showed that HDAC4
was detected in the Sp3 immunocomplex (Fig. 5D). In contrast, DEHP
did not determine any interaction between HDAC3 with Sp3 and
HDAC4 (Fig. 5E).
Cells transfectedwithODNantisense (AS)HDAC4 for 48h effectively
showed a 70% reduction of HDAC4 expression, as compared with
missense controls (MS; Fig. 5F). Interestingly, AS HDAC4 signiﬁcantly
increased Sp3 and reverted the DEHP-induced Sp3 protein decrease
both as compared with MS (Fig. 5G). More importantly, Sp3 immuno-
precipitation followed by Western blot, in cells transfected with AS
HDAC4 and treated with DEHP, revealed an increase in Sp3 acetylation,
in parallel with a reduction in Sp3 ubiquitination, compared with cells
transfected with MS (Figs. 5H,I).Discussion
The present study showed that exposure to DEHP induces a dose-
dependent reduction of cell viability in SH-SY5Y neuroblastoma cells
and in cortical neurons. Interestingly, this effect seems to be rather spe-
ciﬁc for neuronal cells since DEHPdid not exert any toxic effect on oligo-
dendrocytes. DEHP-induced cell viability reduction in SH-SY5Y cells
was accompanied by an increase of cleaved caspase-3, suggesting that
cell death is due to the activation of an apoptotic pathway. Furthermore,
DEHP was able to reduce protein expression of the transcription factor
Sp3. A change in Sp3 expression may be involved in apoptotic mecha-
nisms, as was demonstrated by the overexpression of Sp3 preventing
DEHP-induced cell death in SH-SY5Y cells and in cortical neuron cul-
tures. To our knowledge, this is the ﬁrst evidence showing Sp3 involve-
ment in the neurodetrimental effect of DEHP. These results are in line
with the known Sp3 role which favors neuronal survival. In fact, a
study has shown that Sp1 and Sp3 are anti-apoptotic transcription fac-
tors in cortical neurons during oxidative stress (Ryu et al., 2003) and
participate with Sp4 in the modulation of neurotoxicity resulting from
Fig. 4. Effect of Sp3 overexpression and HDAC4 knock-down on DEHP-induced Sp3 and HDAC 4 increase and on neuronal death in SH-SY5Y cells and cortical neurons. A,B,D,E) Represen-
tative Western blot showing the expression of Sp3 and HDAC4 in SH-SY5Y cells (A,B) and in cortical neurons (D,E) transfected with empty vector pN3 and with pN3 carrying Sp3 cDNA,
with or without 48 h DEHP (50 μM) exposure. C,F) Effect of DEHP in SH-SY5Y cells (C) and in cortical neurons (F) transfected with empty vector pN3, pN3 carrying Sp3 cDNA, HDAC4MS
and HDAC4 ASwith orwithout 48 h exposure DEHP (50 μM) on apoptosis determined using the Annexin Alexa Fluor 488 kit. Bars represent mean± S.E.M. obtained in four independent
experimental sessions. *P b 0.05 vs. CTL, **P b 0.05 vs. DEHP.
196 N. Guida et al. / Toxicology and Applied Pharmacology 280 (2014) 190–198stroke (Maoet al., 2007). Thus, the novelty of ourﬁndings consists in the
exclusive participation of Sp3, without Sp1 and Sp4, in preserving neu-
rons from DEHP-induced neurotoxicity.
Regarding DEHP concentrations tested in the present study, they
were already used by other authors in a mouse neuroblastoma cell
line, with an IC50 approximately of 10 and 100 μM, respectively (Aung
et al., 2014; Lin et al., 2011). Importantly, the minimal risk level of
DEHP is 0.1 mg/kg/day, as reported by the Agency for Toxic substances
and Disease Registry (ATSDR) (Heudorf et al., 2007). This dose corre-
sponds in the mouse brain at a concentration of 7.8 μM (Wu et al.,
2013). It should be underlined that hospital patients undergoing extra-
corporeal membrane oxygenation (ECMO), mechanical ventilation,
total parenteral nutrition (TPN) and multiple transfusions can be ex-
posed to high DEHP levels, resulting in exposures between 0.005 and
8.5 mg/kg bw/day (Cooper et al., 2008). These levels of exposure corre-
spond in the mouse brain to a concentration range (0.4–640 μM) com-
parable to the concentrations used in the present study. Therefore the
doses of DEHP used in this study are relevant to the environmental
level of DEHP exposed to humans. Furthermore, DEHP can penetrate
the blood–brain barrier (BBB); Wu et al. (2013) found DEHP in the
brain homogenates after the administration of 0.1, 1 or 10 mg/kg thus
demonstrating the possibility of DEHP to cross the blood–brain barrier.
In addition, BBB permeability increases following traumatic, ischemic
(Fernández-López et al., 2012) or infectious brain insults, and it may
last from several days to weeks and even years after the acute event
(Korn et al., 2005; Strbian et al., 2008). Moreover, we identiﬁed a possi-
ble mechanism by which Sp3 protein levels were reduced by DEHP inneuroblastoma cells. DEHP neurotoxicity and the reduction in Sp3
protein levels were prevented by the class II HDAC inhibitor MC-1568,
suggesting the involvement of class II HDACs in DEHP-induced Sp3
reduction. Interestingly, the reduction of Sp3 levels is due to its
deacetylation and subsequent ubiquitination, a mechanism in which
HDAC4 seems to be involved. In fact, DEHP exposure did not induce a
change in Sp3 mRNA, whereas it increased Sp3 protein deacetylation
coupled to its ubiquitination. In addition, Sp3 reduction was reverted
by both the proteasome inhibitorMG-132 andMC-1568. HDAC involve-
ment in mechanisms leading to cell toxicity via Sp3 reduction is further
demonstrated by MC-1568 being able to signiﬁcantly prevent DEHP-
induced neurotoxicity. Interestingly, also HDAC4 knock-down was
able to counteract the neurodetrimental effect of DEHP, in SH-SY5Y
neuroblastoma cells and cortical neurons. Our results are in accordance
with previous reports demonstrating that Sp3 acetylation acts as a
switch that controls the repression and activation role of this transcrip-
tion factor (Ammanamanchi et al., 2003). It seems that the process of
Sp3 deacetylation involves HDAC4, since mRNA and protein are in-
creased by DEHP and speciﬁc inhibition of this enzyme, obtained by
ODN (AS) transfection against HDAC4, was able to revert this mecha-
nism. In addition, since Sp3 overexpression did not change DEHP-
induced HDAC4 expression, it could be suggested that in our experi-
mental conditions Sp3 is not involved in gene regulation of the enzyme
expression. Therefore DEHP-induced increase of HDAC4 mRNA levels
could be due to the effect on the promoter by a transcriptional mecha-
nism that did not involve Sp3. Furthermore, we showed that Sp3 phys-
ically interacted with HDAC4 during DEHP exposure. Interestingly,
Fig. 5. Effect of HDAC4 knock-down onDEHP-induced Sp3 reduction in SH-SY5Y cells. A,B) Effect of 24 and 48 hDEHP (50 μM)exposures onHDAC/class I and IImRNA expression detected
by qRT-PCR. Bars represent mean ± S.E.M. obtained from four for class I and ﬁve for class II independent experimental sessions. *P b 0.05 vs. CTL. C) Western blots of HDAC4 levels in
control conditions and with 50 μMDEHP at 24 and 48 h. Graphs show the quantiﬁcation of the ratio of HDAC4 to tubulin. Bars representmean± S.E.M. obtained from three independent
experimental sessions. *P b 0.05 vs. CTL. D) RepresentativeWestern blot showing the immunoprecipitation of Sp3 and HDAC4 after 24 h treatment with 50 μM DEHP. E) Representative
Western blot showing the immunoprecipitation of HDAC3with Sp3 andwithHDAC4 after 24h treatmentwith 50 μMDEHP. F) Effect of antisense (AS) andmissense (MS) forHDAC4 on its
protein expression. G) Effect of AS andMS forHDAC4 on Sp3 protein expression,with DEHP alone (50 μM)or in combinationwith ASHDAC4. Bars representmean± S.E.M. obtained from
three independent experimental sessions. *Pb 0.05 vs. CTL, **P b 0.05 vs. DEHP.H,I) Immunoprecipitationwith anti-Sp3probed for HDAC4 byWestern blot after 24 h treatmentwith DEHP
alone or in combination with AS HDAC4.
197N. Guida et al. / Toxicology and Applied Pharmacology 280 (2014) 190–198DEHP-induced Sp3 binding reduction to two known Sp3 target genes
Ngb (Zhang et al., 2011) and COX-2 (Lee et al., 2006) is reverted by
pre-treatment with MC-1568, a well known class II HDAC inhibitor
(Spallotta et al., 2013). Notably, MC-1568 also reverted DEHP-induced
COX-2 and Ngb mRNA decrease, respectively. A possible mechanism
bywhich Sp3 reduction results in DEHP-induced cell deathmay involve
Ngb and COX-2 decrease, since both are neuroprotective (Fordel et al.,
2006; Lee et al., 2006). It should be noted that inNeuro2a cells, DEHPac-
tivates Trim17protein via PPARγ, leading to pro-caspase-3 cleavage and
apoptosis, which has been postulated to impair fetal brain development
(Lin et al., 2011). Collectively, the results of the present study suggest
that apoptotic DEHP-induced neuronal cell death is dependent on a re-
duction in Sp3 protein levels which requires HDAC4. Moreover, our
ﬁndings suggest that HDAC4 binding to Sp3 reduces Sp3 acetylation,
while increasing its ubiquitination.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2014.07.014.
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